Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis

NCT03402399 is registered in ClinicalTrials.gov with Assaf-Harofeh Medical Center as lead sponsor.

NCT NCT03402399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03402399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis
Lead sponsor
Assaf-Harofeh Medical Center
Phase
Not applicable
Overall status
Unknown status
Start date
December 10, 2017
Completion date
December 9, 2020
Enrollment
222 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, post et, myelofibrosis, post pv, myelofibrosis, primary